Phillip M Sass

Title: The Innovative Contributions of Phillip M Sass

Introduction

Phillip M Sass is a notable inventor in the field of biotechnology, particularly recognized for his work involving antibodies with immune effector activity. His innovative approach focuses on the use of monoclonal and polyclonal antibodies that target folate receptor alpha-positive cells. This work has significant implications for cancer treatment and targeted drug delivery.

Latest Patents

Phillip M Sass currently holds no patents. However, his invention titled "Antibodies With Immune Effector Activity And That Internalize In Folate Receptor Alpha-Positive Cells" showcases his expertise. This invention relates to antibodies that can bind to and internalize in cells expressing folate receptor alpha, inducing immune effector activities such as antibody-dependent cellular cytotoxicity. The antibodies developed through this research are particularly useful for delivering pharmacologic agents to FRA-expressing cells and eliciting immune responses against tumor cells.

Career Highlights

Phillip M Sass is associated with Eisai Inc., a company dedicated to innovative pharmaceutical solutions. His work at Eisai Inc. emphasizes the development of therapeutic strategies that leverage the immune system to combat cancer. His contributions to the field are marked by a commitment to advancing cancer treatment methodologies.

Collaborations

Phillip M Sass has collaborated with esteemed colleagues such as Luigi Grasso and Nicholas C Nicolaides. These collaborations have fostered a productive environment for research and innovation in the field of immunotherapy.

Conclusion

Phillip M Sass's work in antibody development represents a significant advancement in cancer treatment strategies. His innovative approach to targeting specific cells with immune effector activity holds promise for improving therapeutic outcomes in oncology.